Use orotic acid in the treatment of pathological conditions associated with hyperuricemia

Authors

  • D.D. Ivanov Department of Nephrology and Renal Replacement Therapy, National Medical Academy of Postgraduate Education named after P.L. Shupik, Kyiv, Ukraine http://orcid.org/0000-0003-2609-0051
  • Ya.A. Dombrovskyi Kyiv City Hospital № 18

DOI:

https://doi.org/10.22141/2307-1257.0.4.10.2014.76056

Keywords:

hyperuricemia, gout, urolithiasis, orotic acid

Abstract

Hyperuricemia - a condition characterized by elevated relative to normal ranges, levels of uric acid in the blood. Among the diseases caused by hyperuricemia, most noteworthy are gout, urate nephropathy, and urolithiasis. The topic of this article is devoted to the comparative characteristics of drugs used to correct hyperuricemia. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of using orotic acid agents.

Downloads

Download data is not yet available.

References

Richards J., Weinman E.J. Uric acid and renal disease // J. Nephrol. — 1966. — 9. — 160-166.

Кинев К. Подагра. — М.: Медицина, 1980. — С. 128.

McAdams DeMarco M.A., Maynard J.W., Baer A.N., Gelber A.C., Young J.H., Alonso A. et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study // Arthritis Rheum. — 2012. — 64. — 121-9.

Mateus M.P., Cruz C.M., Alves de Matos A.C. et al. Prevalence and characterization of uric gout disease in a rheumatology outpatient’s clinic // Ann. Rheum. Dis. — 2001. — Vol. 60 (Suppl. 1). — 328.

Коваленко В.М., Шуба Н.М., Корнацький В.М. Сучасний стан ревматологічної служби в Україні // Укр. ревматол. журн. — 2001. — Т. 5–6, № 3–4. — С. 3-7.

Krishnan E. Chronic kidney disease and risk of incident gout among middle-aged men: a seven-year prospective observational study // Arthritis Rheum. — 2013. — 65. — 3271-3278.

Juraschek S.P., Kovell L.C., Miller E.R. et al. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010 // Semin. Arthritis Rheum. — 2013. — 42. — 551-561.

Obermayr R.P., Temml C., Gutjahr G. et al. Elevated uric acid increases the risk for kidney disease // J. Am. Soc. Nephrol. — 2008. — 19. — 2407-2413.

Feig D.I. Uric acid: a novel mediator and marker of risk in chronic kidney disease? // Curr. Opin. Nephrol. Hypertens. — 2009 Nov. — 18(6). — 526-530.

Moriwaki Y. Effects on uric acid metabolism of the drugs except the antihyperuricemics // J. Bioequiv. Availab. — 2014. — 6 (1). — 10-17. doi: 10.4172 jbb.1000173

Kong L.D., Cai Y., Huang W.W. et al. Inhibition of xanthine oxidase by some chinese medicinal plants used to treat gout // J. Ethnopharmacol. — 2000. — 1–2. — 199-207.

Khanna D., Fitzgerald J.D., Khanna P.P. et al. American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia // Arthritis Care Res. — 2012. — 64. — 1431-4446.

Choi H.K. A prescription for lifestyle change in patients with hyperuricemia and gout // Curr. Opin. Rheum. — 2010. — 22. — 165-172.

Keitel R., Keitel W. Therapy of gout. Management of an acute attack — secondary prevention // MMW Fortschr. Med. — 2000. — 142 (12). — 48-50.

Dalbeth N., Wong S., Gamble G.D., Horne A., Mason B., Pool B., Fairbanks L., McQueen F.M., Cornish J., Reid I.R., Palmano K. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial // Annals of the rheumatic diseases. — 2010. — 69 (9). — 1677-82.

Rosenfeldt F.L. Metabolic supplementation with orotic acid and magnesium orotate // Cardiovasc. Drugs Ther. — 1998. — 12 Suppl. 2. — 147-52.

Gaĭsin I.R., Valeeva R.M., Maksimov N.I., Iskhakova A.S., Khodyrev L.A., Shilina L.V. Magnesium orotate in treatment of chronic hypertension in pregnant women // Kardiologiia. — 2013. — 53 (9). — 33-9.

Stepura O.B., Martynow A.I. Magnesium orotate in severe congestive heart failure (MACH) // International Journal of Cardio­logy. — 2009. — 134 (1). — 145-7.

Martynov A.I., Akatova E.V. Fifteen years experience of the use of magnesium preparations in patients with mitral valve prolapse // Kardiologiia. — 2011. — 51(6). — 60-5.

Jellinek H., Takаcs E. Morphological aspects of the effects of orotic acid and magnesium orotate on hypercholesterolaemia in rabbits // Arzneimittelforschung. — 1995. — 45(8). — 836-42.

Published

2022-02-14

How to Cite

Ivanov, D., & Dombrovskyi, Y. (2022). Use orotic acid in the treatment of pathological conditions associated with hyperuricemia. KIDNEYS, (4.10), 55–58. https://doi.org/10.22141/2307-1257.0.4.10.2014.76056

Issue

Section

To Help the Practitioner